Dr McDonagh has published a piece in the Financial Times on Intellectual Property Law and the blockbuster drug Ozempic. Dr McDonagh argues that Novo Nordisk’s recent escalation of lawsuits against the US compounding pharmacies that sell discounted "copycat" weight loss medication has raised an important question about pharmaceutical intellectual property. How should we balance corporate R&D incentives with fair access to drugs?
Click here to read article in full.